Inve India ▾

Sanofi Consumer Healthcare India share price & results

Sanofi Consumer Healthcare India Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q3 FY26
Ownership as of
Sept 2026

India's Sanofi-origin consumer healthcare (FMCH) firm behind Allegra, Combiflam, Avil and DePURA.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue236 ₹ crore+6.8% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin38.0 %+6.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit69.0 ₹ crore+13.1% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity76.44 %−12.0 ptsFY Dec 2025 vs FY Dec 2024Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin19.07 %−40.2 ptsFY Dec 2025 vs FY Dec 2024Fiscal yearFY ending Dec 2025(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)31.03 %—Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

5 targets tracked, none judged yet · 5 open · verdicts reflect calls analysed to Q3 FY26.

Sanofi Consumer Healthcare India Limited management guidance track record on Inve: 5 targets tracked across analysed earnings calls (0 achieved, 0 missed, 5 open).

TargetOriginal wordingSaidLatest callVerdict
Face-to-face doctor (HCP) reachDouble face-to-face doctor reach from current levels in 2026 ('This year itself')
Call transcript, Q3 FY26 · 24 Mar 2026		Q3 FY26Q3 FY26:Hard target to double face-to-face HCP reach in 2026. Baseline not disclosed, so progress cannot be verified numerically.
Call transcript, Q3 FY26 · 24 Mar 2026		New

Source: Inve Guidance Tracker for Sanofi Consumer Healthcare India Limited · to Q3 FY26

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

5 of Sanofi Consumer Healthcare India Limited's 5 targets are still open. See which are on track and which have gone quiet. The 1 above are the free sample; 4 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹3,249.7 +1.30% · +₹41.8

Last close 26 Oct 2026 · NSE · INR · Source: Inve

Performance −30.1% 1Y

₹3.5k₹4.0k₹4.5k₹5.0kOct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q3 FY26 — 24 Mar 2026

1Y: ₹4,651.8 on 24 Oct 2025 → ₹3,249.7. High ₹5,026.8 (14 May 2026), low ₹3,207.9 (23 Oct 2026).

Previous close
₹3,207.9
Market cap
₹7.5k Cr
52-week range
₹3,207.9 – ₹5,026.8
One year
−30.22%
Price to earnings (TTM to Jun 2026)
28.14×
Return on equity (TTM to Jun 2026)
76.44%

Overview

Symbol
NSE:SANOFICONR
Exchange
NSE
Currency
INR

What Sanofi Consumer Healthcare India Limited does

Based on the company's own presentations, annual report and earnings calls.

Sanofi Consumer Healthcare India Limited (SCHIL) is a fast-moving consumer healthcare (FMCH) company selling over-the-counter, self-care brands across allergy relief, pain management, vitamins/minerals/supplements and digestive health. It earns by selling these branded medicines and supplements through pharmacies, hospitals, modern trade and e-commerce channels, and also exports select brands. The company was demerged from Sanofi India's consumer healthcare business (completed 2024) and is majority owned by Opella Healthcare Participations B.V., following CD&R Group's acquisition of controlling stake in the global Opella business.

Segments

  • Allergy Care
  • Pain Care
  • Physical Wellness (VMS)
  • Digestive Health
Cities served
206
Employees
597
Healthcare categories
4
Packs sold per second
400+
Products ranked in Top 300 (Indian consumer healthcare market)
2 (Allegra, Combiflam)
Doctor (HCP) digital reach
50,000+ healthcare professionals
Founded 2023Headquarters Mumbai, MaharashtraEmployees 597 (FY2025 (year ended 31 De) Company website

How the price took the results

close before → close after

Q3 FY26
+1.8%
24 Mar

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Sanofi Consumer Healthcare India Limited

Free account: one company. Everything above stays public.

Write why you follow Sanofi Consumer Healthcare India Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Sanofi Consumer Healthcare India Limited

Guides on how to read this kind of business and the numbers that matter.